MDWD ▲ +1.2% - MediWound Ltd. $MDWD - Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification MediWound rose 1.2% following news that an independent Data Safety Monitoring Board recommended its Phase III VALUE study of EscharEx continue without modification, a signal that the trial met safety and efficacy benchmarks at its interim review. The green light from the DSMB removes a potential near-term risk to the wound-care product candidate's development path. 14-SEP-2026 07:00 AM ET